{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:01:07Z","timestamp":1791352867098,"version":"4.3.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,10,14]],"date-time":"2016-10-14T00:00:00Z","timestamp":1476403200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"No Funding Source"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s40263-016-0386-8","type":"journal-article","created":{"date-parts":[[2016,10,14]],"date-time":"2016-10-14T15:00:29Z","timestamp":1476457229000},"page":"1079-1095","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Novel Levodopa Formulations for Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"30","author":[{"given":"Maria Eliza","family":"Freitas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ruiz-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan H.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,14]]},"reference":[{"key":"386_CR1","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1007\/s00415-010-5741-y","volume":"257","author":"O Hornykiewicz","year":"2010","unstructured":"Hornykiewicz O. A brief history of levodopa. J Neurol. 2010;257:S249\u201352.","journal-title":"J Neurol."},{"key":"386_CR2","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1007\/s00415-010-5728-8","volume":"257","author":"M Contin","year":"2010","unstructured":"Contin M, Martinelli P. Pharmacokinetics of levodopa. J Neurol. 2010;257:S253\u201361.","journal-title":"J Neurol."},{"key":"386_CR3","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1517\/14656566.2015.1111336","volume":"16","author":"LC Seeberger","year":"2015","unstructured":"Seeberger LC, Hauser RA. Carbidopa levodopa enteral suspension. Expert Opin Pharmacother. 2015;16:2807\u201317.","journal-title":"Expert Opin Pharmacother."},{"issue":"Suppl 11","key":"386_CR4","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1002\/mds.20459","volume":"20","author":"K Widnell","year":"2005","unstructured":"Widnell K. Pathophysiology of motor fluctuations in Parkinson\u2019s disease. Mov Disord. 2005;20(Suppl 11):S17\u201322.","journal-title":"Mov Disord."},{"key":"386_CR5","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1017\/S0317167100032170","volume":"18","author":"JT Hutton","year":"1991","unstructured":"Hutton JT, Morris JL. Long-term evaluation of Sinemet CR in parkinsonian patients with motor fluctuations. Can J Neurol Sci. 1991;18:467\u201371.","journal-title":"Can J Neurol Sci."},{"key":"386_CR6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1212\/WNL.39.1.25","volume":"39","author":"KC Yeh","year":"1989","unstructured":"Yeh KC, August TF, Bush DF, Titus DC. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology. 1989;39:25\u201338.","journal-title":"Neurology."},{"key":"386_CR7","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1474-4422(13)70025-5","volume":"12","author":"RA Hauser","year":"2013","unstructured":"Hauser RA, Hsu A, Kell S, Espay AJ, Sethi K, Stacy M, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson\u2019s disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol. 2013;12:346\u201356.","journal-title":"Lancet Neurol."},{"key":"386_CR8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.parkreldis.2013.08.017","volume":"20","author":"R Pahwa","year":"2014","unstructured":"Pahwa R, Lyons KE, Hauser RA, Fahn S, Jankovic J, Pourcher E, et al. Randomized trial of IPX066, carbidopa\/levodopa extended release, in early Parkinson\u2019s disease. Parkinsonism Relat Disord. 2014;20:142\u20138.","journal-title":"Parkinsonism Relat Disord."},{"key":"386_CR9","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/mds.23861","volume":"26","author":"RA Hauser","year":"2011","unstructured":"Hauser RA, Ellenbogen AL, Metman LV, Hsu A, O\u2019Connell MJ, Modi NB, et al. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson\u2019s disease. Mov Disord. 2011;26:2246\u201352.","journal-title":"Mov Disord."},{"key":"386_CR10","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/jcph.63","volume":"53","author":"Z Mao","year":"2013","unstructured":"Mao Z, Hsu A, Gupta S, Modi NB. Population pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson\u2019s disease. J Clin Pharmacol. 2013;53:523\u201331.","journal-title":"J Clin Pharmacol."},{"key":"386_CR11","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/jcph.514","volume":"55","author":"A Hsu","year":"2015","unstructured":"Hsu A, Yao H-M, Gupta S, Modi NB. Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(\u00ae)), sustained-release carbidopa-levodopa (Sinemet\u00ae CR), and carbidopa-levodopa-entacapone (Stalevo\u00ae). J Clin Pharmacol. 2015;55:995\u20131003.","journal-title":"J Clin Pharmacol."},{"key":"386_CR12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/WNF.0000000000000126","volume":"39","author":"H-M Yao","year":"2016","unstructured":"Yao H-M, Hsu A, Gupta S, Modi NB. Clinical pharmacokinetics of IPX066: evaluation of dose proportionality and effect of food in healthy volunteers. Clin Neuropharmacol. 2016;39:10\u20137.","journal-title":"Clin Neuropharmacol."},{"key":"386_CR13","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.parkreldis.2014.08.004","volume":"20","author":"F Stocchi","year":"2014","unstructured":"Stocchi F, Hsu A, Khanna S, Ellenbogen A, Mahler A, Liang G, et al. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Parkinsonism Relat Disord. 2014;20:1335\u201340.","journal-title":"Parkinsonism Relat Disord."},{"key":"386_CR14","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3233\/JPD-150622","volume":"5","author":"PA Nausieda","year":"2015","unstructured":"Nausieda PA, Hsu A, Elmer L, Gil RA, Spiegel J, Singer C, et al. Conversion to IPX066 from standard levodopa formulations in advanced Parkinson\u2019s disease: experience in clinical trials. J Parkinsons Dis. 2015;5:837\u201345.","journal-title":"J Parkinsons Dis."},{"key":"386_CR15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40263-015-0306-3","volume":"30","author":"SL Greig","year":"2016","unstructured":"Greig SL, McKeage K. Carbidopa\/levodopa ER capsules (Rytary\u00ae, Numient\u2122): a review in Parkinson\u2019s disease. CNS Drugs. 2016;30:79\u201390.","journal-title":"CNS Drugs."},{"key":"386_CR16","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40263-015-0242-2","volume":"29","author":"CH Waters","year":"2015","unstructured":"Waters CH, Nausieda P, Dzyak L, Spiegel J, Rudzinska M, Silver DE, et al. Long-term treatment with extended-release carbidopa-levodopa (IPX066) in early and advanced Parkinson\u2019s disease: a 9-month open-label extension trial. CNS Drugs. 2015;29:341\u201350.","journal-title":"CNS Drugs."},{"issue":"Suppl. 1","key":"386_CR17","first-page":"S408","volume":"27","author":"PA LeWitt","year":"2012","unstructured":"LeWitt PA, Friedman H, Giladi N. Accordion pill carbidopa\/levodopa for improved treatment of advanced Parkinson\u2019s disease symptoms [abstract]. Mov Disord. 2012;27(Suppl. 1):S408.","journal-title":"Mov Disord"},{"issue":"Suppl. 1","key":"386_CR18","first-page":"S499","volume":"28","author":"P LeWitt","year":"2013","unstructured":"LeWitt P, Friedman H, Giladi N. Sustained-release carbidopa-levodopa (accordian pill) in patients with advanced Parkinson\u2019s disease: pharmacokinetic and clinical experience [abstract]. Mov Disord. 2013;28(Suppl. 1):S499.","journal-title":"Mov Disord."},{"issue":"Suppl. 1","key":"386_CR19","first-page":"S668","volume":"29","author":"PA LeWitt","year":"2014","unstructured":"LeWitt PA, Giladi N, Gurevich T. Accordion pill carbidopa\/levodopa (AP-CD\/LD) for treatment of advanced Parkinson\u2019s disease (PD) [abstract]. Mov Disord. 2014;29(Suppl. 1):S668.","journal-title":"Mov Disord."},{"key":"386_CR20","first-page":"459","volume":"20","author":"SYE Hou","year":"2003","unstructured":"Hou SYE, Cowles VE, Berner B. Gastric retentive dosage forms: a review. Crit Rev Ther Drug Carrier Syst. 2003;20:459\u201397.","journal-title":"Crit Rev Ther Drug Carrier Syst."},{"key":"386_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10837450601168680","volume":"12","author":"KC Waterman","year":"2007","unstructured":"Waterman KC. A critical review of gastric retentive controlled drug delivery. Pharm Dev Technol. 2007;12:1\u201310.","journal-title":"Pharm Dev Technol."},{"key":"386_CR22","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1517\/17425247.2011.592828","volume":"8","author":"P Prinderre","year":"2011","unstructured":"Prinderre P, Sauzet C, Fuxen C. Advances in gastro retentive drug-delivery systems. Expert Opin Drug Deliv. 2011;8:1189\u2013203.","journal-title":"Expert Opin Drug Deliv."},{"key":"386_CR23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/WNF.0b013e31824523de","volume":"35","author":"C Chen","year":"2012","unstructured":"Chen C, Cowles VE, Sweeney M, Stolyarov ID, Illarioshkin SN. Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa\/carbidopa in patients with Parkinson disease. Clin Neuropharmacol. 2012;35:67\u201372.","journal-title":"Clin Neuropharmacol."},{"key":"386_CR24","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/mds.26219","volume":"30","author":"L Verhagen Metman","year":"2015","unstructured":"Verhagen Metman L, Stover N, Chen C, Cowles VE, Sweeney M. Gastroretentive carbidopa\/levodopa, DM-1992, for the treatment of advanced Parkinson\u2019s disease. Mov Disord. 2015;30:1222\u20138.","journal-title":"Mov Disord."},{"key":"386_CR25","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1177\/0091270011409232","volume":"52","author":"C Chen","year":"2012","unstructured":"Chen C, Cowles VE, Sweeney M, Stolyarov ID, Illarioshkin SN. Pharmacokinetics of levodopa\/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson\u2019s disease. J Clin Pharmacol. 2012;52:1069\u201377.","journal-title":"J Clin Pharmacol."},{"key":"386_CR26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/WNF.0b013e31824e4d7d","volume":"35","author":"PA Lewitt","year":"2012","unstructured":"Lewitt PA, Ellenbogen A, Chen D, Lal R, McGuire K, Zomorodi K, et al. Actively transported levodopa prodrug XP21279. Clin Neuropharmacol. 2012;35:103\u201310.","journal-title":"Clin Neuropharmacol."},{"key":"386_CR27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/mds.25742","volume":"29","author":"PA Lewitt","year":"2014","unstructured":"Lewitt PA, Huff FJ, Hauser RA, Chen D, Lissin D, Zomorodi K, et al. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson\u2019s disease. Mov Disord. 2014;29:75\u201382.","journal-title":"Mov Disord."},{"key":"386_CR28","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.1002\/mds.25213","volume":"28","author":"T Muller","year":"2013","unstructured":"Muller T, Kuoppamaki M, Vahteristio M, Aho V. Novel levodopa product ODM-101 vs levodopa\/carbidopa\/entacapone in Parkinson\u2019s disease with response fluctuations. Mov Disord. 2013;28:S146.","journal-title":"Mov Disord."},{"key":"386_CR29","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1212\/01.WNL.0000149637.70961.4C","volume":"64","author":"D Nyholm","year":"2005","unstructured":"Nyholm D, Nilsson Remahl AIM, Dizdar N, Constantinescu R, Holmberg B, Jansson R, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005;64:216\u201323.","journal-title":"Neurology."},{"key":"386_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40263-015-0305-4","volume":"30","author":"K Wirdefeldt","year":"2016","unstructured":"Wirdefeldt K, Odin P, Nyholm D. Levodopa-carbidopa intestinal gel in patients with Parkinson\u2019s disease: a systematic review. CNS Drugs. 2016;30:1\u201324.","journal-title":"CNS Drugs"},{"key":"386_CR31","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/bcp.12324","volume":"78","author":"AA Othman","year":"2014","unstructured":"Othman AA, Dutta S. Population pharmacokinetics of levodopa in subjects with advanced Parkinson\u2019s disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. Br J Clin Pharmacol. 2014;78:94\u2013105.","journal-title":"Br J Clin Pharmacol."},{"key":"386_CR32","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1208\/s12248-012-9439-1","volume":"15","author":"D Nyholm","year":"2013","unstructured":"Nyholm D, Odin P, Johansson A, Chatamra K, Locke C, Dutta S, et al. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease patients. AAPS J. 2013;15:316\u201323.","journal-title":"AAPS J."},{"key":"386_CR33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13:141\u20139.","journal-title":"Lancet Neurol."},{"key":"386_CR34","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.parkreldis.2012.11.020","volume":"19","author":"HH Fernandez","year":"2013","unstructured":"Fernandez HH, Vanagunas A, Odin P, Espay AJ, Hauser RA, Standaert DG, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease open-label study: interim results. Parkinsonism Relat Disord. 2013;19:339\u201345.","journal-title":"Parkinsonism Relat Disord."},{"key":"386_CR35","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.parkreldis.2014.12.012","volume":"21","author":"A Antonini","year":"2015","unstructured":"Antonini A, Yegin A, Preda C, Bergmann L, Poewe W, GLORIA study investigators and coordinators. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson\u2019s disease patients; 12-month interim outcomes. Parkinsonism Relat Disord. 2015;21:231\u20135.","journal-title":"Parkinsonism Relat Disord."},{"key":"386_CR36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00415-012-6597-0","volume":"260","author":"M Zibetti","year":"2013","unstructured":"Zibetti M, Merola A, Ricchi V, Marchisio A, Artusi CA, Rizzi L, et al. Long-term duodenal levodopa infusion in Parkinson\u2019s disease: a 3-year motor and cognitive follow-up study. J Neurol. 2013;260:105\u201314.","journal-title":"J Neurol."},{"key":"386_CR37","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/ene.12309","volume":"21","author":"M Zibetti","year":"2014","unstructured":"Zibetti M, Merola A, Artusi CA, Rizzi L, Angrisano S, Reggio D, et al. Levodopa\/carbidopa intestinal gel infusion in advanced Parkinson\u2019s disease: a 7-year experience. Eur J Neurol. 2014;21:312\u20138.","journal-title":"Eur J Neurol."},{"key":"386_CR38","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/mds.26123","volume":"30","author":"HH Fernandez","year":"2015","unstructured":"Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VSC, Klostermann F, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease: final 12-month, open-label results. Mov Disord. 2015;30:500\u20139.","journal-title":"Mov Disord."},{"key":"386_CR39","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.parkreldis.2013.08.007","volume":"20","author":"I Galazky","year":"2014","unstructured":"Galazky I, Schoof J, Stallforth S, Kupsch A, Heinze H-J, Kluge C. Guillain\u2013Barre\/CIDP-like neuropathy in two parkinsonian patients following intestinal levodopa\/carbidopa treatment. Parkinsonism Relat Disord. 2014;20:125\u20137.","journal-title":"Parkinsonism Relat Disord."},{"key":"386_CR40","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1002\/mds.22807","volume":"24","author":"D Manca","year":"2009","unstructured":"Manca D, Cossu G, Murgia D, Molari A. Reversible encephalopathy and axonal neuropathy in Parkinson\u2019s disease during duodopa therapy. Mov Disord. 2009;24:2289\u2013308.","journal-title":"Mov Disord."},{"key":"386_CR41","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/mds.23342","volume":"25","author":"PP Urban","year":"2010","unstructured":"Urban PP, Wellach I, Faiss S, Layer P. Subacute axonal neuropathy in Parkinson\u2019s disease with cobalamin and vitamin B6 deficiency under duodopa therapy. Mov Disord. 2010;25:1744\u201352.","journal-title":"Mov Disord."},{"key":"386_CR42","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00702-014-1204-4","volume":"121","author":"SM Lehnerer","year":"2014","unstructured":"Lehnerer SM, Fietzek UM, Messner M, Ceballos-Baumann AO. Subacute peripheral neuropathy under duodopa therapy without cobalamin deficiency and despite supplementation. J Neural Transm. 2014;121:1269\u201372.","journal-title":"J Neural Transm."},{"key":"386_CR43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.parkreldis.2013.09.007","volume":"20","author":"F Mancini","year":"2014","unstructured":"Mancini F, Comi C, Oggioni GD, Pacchetti C, Calandrella D, Coletti Moja M, et al. Prevalence and features of peripheral neuropathy in Parkinson\u2019s disease patients under different therapeutic regimens. Parkinsonism Relat Disord. 2014;20:27\u201331.","journal-title":"Parkinsonism Relat Disord."},{"key":"386_CR44","doi-asserted-by":"crossref","first-page":"e66639","DOI":"10.1371\/journal.pone.0066639","volume":"8","author":"C Jugel","year":"2013","unstructured":"Jugel C, Ehlen F, Taskin B, Marzinzik F, M\u00fcller T, Klostermann F. Neuropathy in Parkinson\u2019s disease patients with intestinal levodopa infusion versus oral drugs. PLoS One. 2013;8:e66639.","journal-title":"PLoS One."},{"key":"386_CR45","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/jnnp-2014-308586","volume":"86","author":"A Uncini","year":"2015","unstructured":"Uncini A, Eleopra R, Onofrj M. Polyneuropathy associated with duodenal infusion of levodopa in Parkinson\u2019s disease: features, pathogenesis and management. J Neurol Neurosurg Psychiatr. 2015;86:490\u20135.","journal-title":"J Neurol Neurosurg Psychiatr."},{"issue":"Suppl. 1","key":"386_CR46","first-page":"S452","volume":"28","author":"Y Caraco","year":"2013","unstructured":"Caraco Y, Oren S, LeWitt P. Constant therapeutic levodopa (LD) plasma concentrations maintained by continuous subcutaneous (SC) administration of ND-0612, a novel formulation of LD\/carbidopa (CD) [abstract]. Mov Disord. 2013;28(Suppl. 1):S452.","journal-title":"Mov Disord"},{"key":"386_CR47","doi-asserted-by":"crossref","unstructured":"Giladi N, Caraco Y, Gurevich T, Djaldetti R. Pharmacokinetics and safety of ND0612L (levodopa\/carbidopa for subcutaneous infusion): results from a phase II study in moderate to severe Parkinson\u2019s disease [abstract]. Neurology. 2015;84(Suppl. P1):187.","DOI":"10.1212\/WNL.84.14_supplement.P1.187"},{"key":"386_CR48","first-page":"1995","volume":"30","author":"N Giladi","year":"2015","unstructured":"Giladi N, Caraco Y, Gurevich T, Djaldetti R, Olanow CW. Stable levodopa plasma levels with ND0612 (levodopa\/carbidopa for subcutaneous infusion) in Parkinson\u2019s disease (PD) patients with motor fluctuations [abstract]. Mov Disord. 2015;30:1995.","journal-title":"Mov Disord."},{"key":"386_CR49","doi-asserted-by":"crossref","unstructured":"Giladi N, Caraco Y, Gurevich T. Pharmacokinetic profile of ND0612L (levodopa\/carbidopa for subcutaneous infusion) in patients with moderate to severe Parkinson\u2019s disease [abstract]. Mov Disord 2015;30(Suppl. 1):S226.","DOI":"10.1212\/WNL.84.14_supplement.P1.187"},{"key":"386_CR50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejpb.2015.10.003","volume":"97","author":"M Luinstra","year":"2015","unstructured":"Luinstra M, Grasmeijer F, Hagedoorn P, Moes JR, Frijlink HW, de Boer AH. A levodopa dry powder inhaler for the treatment of Parkinson\u2019s disease patients in off periods. Eur J Pharm Biopharm. 2015;97:22\u20139.","journal-title":"Eur J Pharm Biopharm."},{"key":"386_CR51","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/mds.26611","volume":"31","author":"PA Lewitt","year":"2016","unstructured":"Lewitt PA, Hauser RA, Grosset DG, Stocchi F, Saint-Hilaire M-H, Ellenbogen A, et al. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson\u2019s disease. Mov Disord. 2016;31:1356\u201365.","journal-title":"Mov Disord."},{"key":"386_CR52","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1212\/WNL.0000000000002510","volume":"86","author":"R Dhall","year":"2016","unstructured":"Dhall R, Kreitzman DL. Advances in levodopa therapy for Parkinson disease: review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Neurology. 2016;86:S13\u201324.","journal-title":"Neurology."},{"key":"386_CR53","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1001\/archneur.58.9.1385","volume":"58","author":"RB Dewey","year":"2001","unstructured":"Dewey RB, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for Parkinsonian off-state events. Arch Neurol. 2001;58:1385\u201392.","journal-title":"Arch Neurol."},{"key":"386_CR54","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2165\/00023210-200822060-00005","volume":"22","author":"RM Trosch","year":"2008","unstructured":"Trosch RM, Silver D, Bottini PB. Intermittent subcutaneous apomorphine therapy for \u2018off\u2019 episodes in Parkinson\u2019s disease: a 6-month open-label study. CNS Drugs. 2008;22:519\u201327.","journal-title":"CNS Drugs."},{"key":"386_CR55","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00002826-199704000-00008","volume":"20","author":"M Merello","year":"1997","unstructured":"Merello M, Pikielny R, Cammarota A, Leiguarda R. Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson\u2019s disease patients: a double-blind single-dose study. Clin Neuropharmacol. 1997;20:165\u20137.","journal-title":"Clin Neuropharmacol."},{"key":"386_CR56","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archneur.63.2.210","volume":"63","author":"K Blindauer","year":"2006","unstructured":"Blindauer K, Shoulson I, Oakes D, Kieburtz K, Schwid S, Fahn S, et al. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol. 2006;63:210\u20136.","journal-title":"Arch Neurol."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0386-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-016-0386-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0386-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T23:12:19Z","timestamp":1718838739000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-016-0386-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,14]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["386"],"URL":"https:\/\/doi.org\/10.1007\/s40263-016-0386-8","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,14]]}}}